Bristol-Myers Squibb (NYSE: BMY), in many ways, has led the immuno-oncology revolution with its game-changing checkpoint inhibitors Opdivo and Yervoy. However, the stock has lost a bit of its shine in the past year, thanks to …
Bristol-Myers Squibb Co (NYSE:BMY) stock has had a tumultuous 12-month period. In January, it fell 20% but luckily for the bulls it recovered all of it within five weeks. Since then and after several +/-8% moves, BMY is up 12% in 52 weeks …
Bristol-Myers Squibb Company BMY was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock …
The third-quarter earnings season is off to a strong start. The results of the companies that have reported numbers show that earnings and revenue growth pace is accelerating from the first two quarters. In particular, revenue growth has …